Novo Nordisk A/S

Novo Nordisk Invests $1.09 Billion in Brazil

Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.

Novo Nordisk to Build New Production Facility in Odense, Denmark

Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.

Novo Nordisk to Acquire Cardior Pharmaceuticals

Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

Novo Nordisk to Invest €2.1 Billion in French Production Site

Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.

Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences

Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3 billion.

Novo Nordisk in Talks to Take Majority Stake in Biocorp

Danish drugmaker Novo Nordisk is in exclusive talks to take a controlling stake in Biocorp, a French company specializing in developing and producing delivery systems and medical devices, for about €154 million.

Never Compromise

Anne Phillips Appointed VP of Novo Nordisk's Clinical Development, Medical and Regulatory Affairs for North America